drugset

drugset / Trial / NCT05642949

Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

NCT05642949 ↗

Phase 1/2 Unknown 400 enrolled Minghui Pharmaceutical Pty Ltd

RandomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.

Timeline

Start: 2023-01-23
Primary completion: 2025-12-31
Completion: 2026-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MHB036C	Other / unclassified	—	Intravenous

Indications